An analysis of the Medicaid expansion plans of 6 states that have been granted Section 1115 waivers identified both the promise and limits that have emerged through these alternative expansion approaches.
The Section 1115 demonstration waiver allows states to tailor their Medicaid expansion plans to meet practical and political realities. An analysis of the Medicaid expansion plans of 6 states—Arkansas, Indiana, Iowa, Michigan, New Hampshire, and Pennsylvania—that have been granted the waivers identifies both the promise and limits that have emerged through these alternative expansion approaches.
States looking to expand Medicaid under Section 1115 must still demonstrate that the plan will be consistent with Medicaid objectives, specifically that it will extend coverage to low-income and vulnerable populations. While HHS can approve many of the changes under Section 1115, some need to be left up to Congress, experts wrote in a blog post for The Commonwealth Fund. There 3 specific areas of concern:
Read more at The Commonwealth Fund: http://bit.ly/1dEUrSp
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More